top of page
Publications and Presentations
AAIC 2026: Effect of the P. gingivalis (Pg) gingipain inhibitor atuzaginstat on neuropsychiatric symptoms in Pg-positive mild-moderate Alzheimer's disease patients
ASCP 2026: The Phase 2/3 GAIN trial of the first generation P. gingivalis gingipain inhibitor atuzaginstat in mild to moderate AD: New CSF Biomarker Data and Neuropsychiatric Outcomes
March 31 ,2026
National BrightFocus Event on April 2, 2006 Features Lighthouse Pharma CMO Dr. Michael Detke, discussing the SPRING trial's novel approach to Alzheimer's disease treatment
Haditsch U,et al, 2020. Alzheimer's Disease-Like Neurodegeneration in Porphyromonas gingivalis Infected Neurons with Persistent Expression of Active Gingipains. J Alzheimers Dis. 2020;75(4):1361-1376.
Stephen S. Dominy et al, 2019. Porphyromonas gingivalis in Alzheimer’s disease brains: Evidence for disease causation and treatment with small-molecule inhibitors.Sci. Adv.5,eaau3333 (2019).
bottom of page